Shenzhou Cell Engineering Co Ltd. is a private company headquartered in China. The firm produces monoclonal antibodies, recombinant proteins and vaccines.

Zhaoke Pharmaceutical (Hefei) Co., Ltd., established on 1994-02-07, Business scope includes licensed projects:pharmaceutical production;Drug Wholesale;Drug retail;Drug import and export;Disinfectant production(Free of Hazardous Chemicals);Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Disinfectant sales(Free of Hazardous Chemicals);Sales of Class I Medical Devices;Sales of Class II Medical Devices(Except for licensed business,Can independently operate projects that are not prohibited or restricted by laws and regulations)

Verimmune, Inc. is an American company located in Washington, DC, that operates as a biotechnology company. The firm was founded in 1995 by Joshua Weiyuan Wang and John Troyer. Joshua Weiyuan Wang is the current CEO of the firm.\nThe company says this about itself: VerImmune is an early-stage biotechnology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection (AIR). This strategy utilizes a proprietary virus-inspired particle (ViP) platform that redirects pre-existing pathogenic or childhood vaccine immune memory towards tumors. This unique mechanism of action allows differentiation within the competitive Immuno-Oncology market. Importantly, it potentially changes the treatment paradigm for many patients who have un-treatable cancers due to limited options or resistance.

Beijing Academy of Agriculture & Forestry Sciences is a Chinese private company with domestic subsidiaries, that operates as an agricultural research organization.

VaxInnate Corp. develops novel, proprietary vaccines for infectious diseases. It engages in the development and production of vaccines for pandemic and seasonal influenza diseases. The firm's products include Flagellin.HuHA and flagellin.AvHA, which are fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with immunoprotective domain of viral hemagglutinin. The company was founded by Ruslan Medzhitov, Michael I. Sherman and Richard Flavell in 2002 and is headquartered in Cranbury, NJ.

R.P. Scherer Technologies LLC, a subsidiary of Catalent, Inc., is an American company that develops, manufactures and sells oral, topical, sterile and inhaled forms of drug delivery products.

Pulike Biological Engineering, Inc. engages in the research, development, manufacturing and sale of biological products for animals, chemical drugs and Chinese veterinary drugs. Its products include genetic engineering vaccines and multivalent vaccines. The company also provides technical services. Pulike Biological Engineering was founded in 1995 and is headquartered in Luoyang, China.

Henan Academy of Agricultural Sciences is a Chinese private company located in Zhengzhou. The firm engages in publishing and printing, books and pamphlets.

Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

Novavax is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated the development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’s proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

Shimadzu Enterprise Management (China) Co., Ltd., established on 1999-08-11, The scope of business includes being entrusted by the Shimadzu Group and its companies at home and abroad,provide the following services:Investment and operation decision,Marketing Services,Fund Operation and Financial Management,Technical support and research and development,information service,Staff training and management,Undertake shared services within the group and service outsourcing of overseas companies,engaged in medical equipment,Precision Analytical Instruments,industrial pump,Import and export of industrial boiler products,wholesale,commission agent(except auction),and provide related services,Installation of medical equipment,repair,medical equipment,Precision Analytical Instruments,industrial pump,Storage mainly for industrial boiler products, related products and spare parts(In addition to dangerous goods),Distribution business and technical services for related products,International trade in the region,Re-export trade,Trade and trade agency between enterprises in the region,Simple commercial processing in the region,Product display and business consulting services in the region. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Seek Ltd. researches, develops and sells over the counter and prescription medicines, and manage and operate a number of clinics. The company was founded in and is headquartered in London, the United Kingdom.

With a core business in plasmid DNA and genetic engineering, Delphi Genetics provides services based on unique technologies. To assist you in your viral, and non-viral, gene therapy programs, our dedicated team of scientists develop customized GMP plasmid DNA manufacturing solutions. Their patented STABY® technology without antibiotic resistance gene is the ideal alternative to standard antibiotic-resistance selection and drives better plasmid DNA stabilization.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Benz Biotechnology (Yunnan) Co., Ltd., established on 2004-12-13, Business scope includes biotechnology pharmaceuticals,API,Chinese herbal medicine products and anti-cancer health products,Research on Health Food,to develop.(Except for national prohibitions and restrictions.Business scope involving a license is operated according to a license).